Consensus AbbVie Inc. Thailand S.E.

Stocks

ABBV19

TH8483124005

Pharmaceuticals

End-of-day quote Thailand S.E. 10/09/2026			5-day change	1st Jan Change
8.300 ^THB	0.00%		-4.60%	+13.70%

09-10	Abbvie Declares Quarterly Dividend, Payable on November 16, 2026	CI
09-10	AbbVie Keeps Quarterly Dividend at $1.73 a Share, Payable Nov. 16 to Holders of Record Oct. 15	MT

a1fa07e1f52d68dd3dc2822d3866b7f4.38s4ZsUkXifq4KmjMoBiY76bsbbQzuFrWWg5hnSe9HI.lKwVXp18N0uitPvKQc43NPr-hfe_9rkfYQx48j_drRuyvGgtrmE8FpqLwg~6eee413364577d6bc4fcb30367550b6e

Analysts' recommendations: AbbVie Inc.

09-10	HSBC Adjusts Price Target on AbbVie to $315 From $300, Keeps Buy Rating	MT
09-08	BofA Securities Adjusts Price Target on AbbVie to $282 From $276	MT
08-20	Piper Sandler Adjusts Price Target on AbbVie to $303 From $298, Maintains Overweight Rating	MT
08-17	Wells Fargo Adjusts Price Target on AbbVie to $300 From $295, Keeps Overweight Rating	MT
08-13	Wolfe Upgrades AbbVie to Outperform From Peer Perform, Price Target is $300	MT
08-11	BNP Paribas Adjusts Price Target on AbbVie to $247 From $218, Maintains Neutral Rating	MT
08-05	Argus Lifts AbbVie Price Target to $270 From $250	MT
08-05	Leerink Partners Adjusts Price Target on AbbVie to $279 From $245	MT
08-04	Guggenheim Adjusts Price Target on AbbVie to $288 From $261, Maintains Buy Rating	MT
08-04	Rothschild & Co Redburn Adjusts Price Target on AbbVie to $285 From $284, Maintains Buy Rating	MT
08-03	AbbVie Pipeline Draws Greater Investor Focus After 'Strong' Q2, RBC Says	MT
08-03	Oppenheimer Adjusts AbbVie Price Target to $258 From $244, Maintains Neutral Rating	MT
08-03	Canaccord Genuity Adjusts AbbVie Price Target to $290 From $282, Maintains Buy Rating	MT
07-31	JPMorgan Adjusts Price Target on AbbVie to $285 From $280	MT
07-28	Barclays Adjusts AbbVie PT to $300 From $275, Maintains Overweight Rating	MT
07-22	Canaccord Genuity Adjusts Price Target on AbbVie to $282 From $273, Maintains Buy Rating	MT
07-15	Citigroup Adjusts Price Target on AbbVie to $260 From $230, Maintains Neutral Rating	MT
07-13	BMO Capital Adjusts Price Target on AbbVie to $300 From $258, Maintains Outperform Rating	MT
07-13	UBS Adjusts Price Target on AbbVie to $260 From $230, Maintains Neutral Rating	MT
07-10	Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says	MT
07-10	BofA Securities Adjusts AbbVie Price Target to $276 From $234	MT
07-10	AbbVie's Q2 Results Expected to be Inline With Expectations, RBC Says	MT
07-10	RBC Raises Price Target on AbbVie to $280 From $260, Keeps Outperform Rating	MT
07-10	Wells Fargo Adjusts Price Target on AbbVie to $295 From $260	MT
07-09	JPMorgan Adjusts Price Target on AbbVie to $280 From $260	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ELI LILLY AND COMPANY					+17.02%
	JOHNSON & JOHNSON					+3.71%
	ABBVIE INC.					+10.32%
	ROCHE HOLDING AG					+7.48%
	NOVARTIS AG					+11.26%
	ASTRAZENECA PLC					+34.37%
	AMGEN INC.					-0.65%
	NOVO NORDISK A/S					+7.36%
	GILEAD SCIENCES, INC.					+8.07%
	Average					+10.99%
	Weighted average by Cap.					+11.54%